Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempus AI Cl A (TEM)

Tempus AI Cl A (TEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,768,872
  • Shares Outstanding, K 177,907
  • Annual Sales, $ 693,400 K
  • Annual Income, $ -705,810 K
  • EBIT $ -242 M
  • EBITDA $ -198 M
  • 60-Month Beta 5.22
  • Price/Sales 8.83
  • Price/Cash Flow N/A
  • Price/Book 18.37

Options Overview Details

View History
  • Implied Volatility 75.98% (-3.89%)
  • Historical Volatility 55.62%
  • IV Percentile 34%
  • IV Rank 20.92%
  • IV High 133.93% on 04/08/25
  • IV Low 60.65% on 12/10/25
  • Expected Move (DTE 5) 3.82 (6.95%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 18,041
  • Volume Avg (30-Day) 24,613
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 264,728
  • Open Int (30-Day) 287,599
  • Expected Range 51.09 to 58.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 5
  • High Estimate -0.25
  • Low Estimate -0.33
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +15.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.88 +10.08%
on 02/04/26
76.33 -28.06%
on 01/12/26
-14.63 (-21.04%)
since 01/06/26
3-Month
49.88 +10.08%
on 02/04/26
79.96 -31.33%
on 11/26/25
-17.18 (-23.83%)
since 11/06/25
52-Week
36.22 +51.60%
on 04/09/25
104.32 -47.36%
on 10/09/25
-10.08 (-15.51%)
since 02/06/25

Most Recent Stories

More News
Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes

New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary...

TEM : 54.91 (+4.71%)
Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease

TEM : 54.91 (+4.71%)
Cathie Wood Just Bet $26 Million on Broadcom Stock. Should You Buy AVGO Too?

Cathie Wood bets on Broadcom while shorting major market names in a week of activity.

BLSH : 27.45 (+10.24%)
ARKX : 31.69 (+5.56%)
NFLX : 82.20 (+1.64%)
META : 661.46 (-1.31%)
ROKU : 85.85 (-0.23%)
TXG : 18.61 (+5.14%)
GTLB : 32.13 (+4.97%)
AVGO : 332.92 (+7.22%)
TWST : 49.24 (+4.54%)
ILMN : 119.72 (-10.40%)
CRCL : 57.04 (+13.56%)
WRD : 7.81 (+6.11%)
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune...

TEM : 54.91 (+4.71%)
Pelosi’s Bullish 2026 Buy List: AI, Power & Dividends

The famous congressional portfolio is rotating capital into dividend-paying financial stocks while doubling down on artificial intelligence and energy.

AB : 39.43 (-6.92%)
NVDA : 185.41 (+7.87%)
GOOGL : 322.86 (-2.53%)
AAPL : 278.12 (+0.80%)
VST : 149.65 (+4.60%)
TEM : 54.91 (+4.71%)
AMZN : 210.32 (-5.55%)
Tempus Announces the Launch of Paige Predict

Following the acquisition of Paige in 2025, Tempus launches its new AI-powered, biomarker prediction solution for digital pathology

TEM : 54.91 (+4.71%)
Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology

Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation’s premier academic medical centers, today announced a multi-year strategic collaboration...

TEM : 54.91 (+4.71%)
Northwestern Medicine Selects Tempus to Expand Genomic Testing

Collaboration will focus on the oncology patient population

TEM : 54.91 (+4.71%)
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion

Reported preliminary, unaudited Data and application revenue of ~$316 million for the full year 2025, representing ~31% year-over-year growth, with Insights (data licensing) growing 38% ...

TEM : 54.91 (+4.71%)
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year...

TEM : 54.91 (+4.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed above 30%. The market has bounced from oversold territory. Beware of a potential mean reversion.

See More Share

Business Summary

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery,...

See More

Key Turning Points

3rd Resistance Point 58.58
2nd Resistance Point 57.06
1st Resistance Point 55.99
Last Price 54.91
1st Support Level 53.40
2nd Support Level 51.88
3rd Support Level 50.81

See More

52-Week High 104.32
Fibonacci 61.8% 78.31
Fibonacci 50% 70.27
Fibonacci 38.2% 62.23
Last Price 54.91
52-Week Low 36.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar